Seaport Therapeutics
SPTX
54 hedge funds and large institutions have $815M invested in Seaport Therapeutics in 2026 Q2 according to their latest regulatory filings, with 54 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
70.01% more ownership
Funds ownership: 0% → 70.01% (+70%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AVM
Arch Venture Management
Chicago,
Illinois
|
+$111M |
| 2 |
GA
General Atlantic
New York
|
+$107M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$62.7M |
| 4 |
Goldman Sachs
New York
|
+$38.3M |
| 5 |
TGV
TRV GP VI
Boston,
Massachusetts
|
+$36.3M |
Top Sellers
SPTX Hedge Fund Activity: Q2 2026 in Review
54 of the 8,344 institutional investors tracked by Wall St. Rank reported a position in Seaport Therapeutics (SPTX) for Q2 2026, worth a combined $815M.
Buyers outnumbered sellers: 54 funds opened new SPTX positions and 0 closed out — a net gain of 54 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Arch Venture Management, opening a new position worth an estimated $111M.
- 54 institutional investors held Seaport Therapeutics (SPTX) as of Q2 2026, up from 0 in Q1 2026.
- Funds reported $815M of Seaport Therapeutics stock for Q2 2026.
- 54 funds opened new Seaport Therapeutics positions in Q2 2026 and 0 closed out, a net change of +54 holders.
- The largest Seaport Therapeutics buyer in Q2 2026 was Arch Venture Management, an estimated $111M added.
Based on aggregated 13F filings for Q2 2026.